# Bispecific Antibody

Chasing the Holy Grail: HEC Pharm’s Triple Threat at AACR 2026 Signals China’s Oncology Pivot

HEC Pharm presented three innovative oncology candidates at the 2026 AACR meeting, showcasing breakthroughs in Pan-RAS molecular glues, bispecific antibodies, and oral PD-L1 inhibitors. This move highlights the company's strategic pivot toward high-complexity R&D and its ambition to compete in the global precision medicine market.